Monopar Therapeutics MNPR Increase Decrease In Inprocess Research And Development Accrued Expenses
Increase Decrease In Inprocess Research And Development Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by Monopar Therapeutics in its filing.
Tagged under the XBRL concept mnpr:IncreaseDecreaseInInprocessResearchAndDevelopmentAccruedExpenses.
The official record: Monopar Therapeutics’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →
Ask your AI about Monopar Therapeutics's increase decrease in inprocess research and development accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Monopar Therapeutics's increase decrease in inprocess research and development accrued expenses?
- Monopar Therapeutics (MNPR) reported increase decrease in inprocess research and development accrued expenses of $0 in Q1 2026.
- How has Monopar Therapeutics's increase decrease in inprocess research and development accrued expenses changed year-over-year?
- Monopar Therapeutics's increase decrease in inprocess research and development accrued expenses decreased by 100.0% year-over-year, from $3M to $0.
- What does increase decrease in inprocess research and development accrued expenses mean?
- This represents the change in accrued liabilities specifically related to ongoing research and development projects. It captures the timing differences between the commitment to R&D expenditures and the actual cash disbursement for those services. For clinical-stage companies, this metric is a key indicator of the intensity and stage of development activities.